1. The conjugate containing the targeting peptide and the cytokine, for use in the treatment of mesothelioma, where the targeting peptide is a peptide containing an NGR motif, is DGR or RGD, and where the cytokine is TNFα or TNFβ. ! 2. The conjugate according to claim 1, in which the targeting peptide is a peptide containing an NGR motif. ! 3. The conjugate of claim 2 wherein the targeting peptide is selected from the group consisting of linear or cyclic CNGRCVSGCAGRC, NGRAHA, GNGRG, CVLNGRMEC, CNGRC, CNGRCG, LNGRE, YNGRT LQCICTGNGRGEWKCE, LQCISTGNGRGEWKCE, CICTGNGRGEWKC, CISTGNGRGEWKC, MRCTCVGNGRGEWTCY, MRCTSVGNGRGEWTCY, CTCVGNGRGEWTC and CTSVGNGRGEWTC. ! 4. The conjugate of claim 2 or 3, wherein the cytokine is TNF coupled to the targeting CNGRC peptide via spacer G (glycine). ! 5. A method of treating mesothelioma, comprising administering a conjugate comprising a target peptide and a cytokine, where the target peptide is a peptide containing an NGR motif, is DGR or RGD, and where the cytokine is TNFα or TNFβ. ! 6. A pharmaceutical composition comprising an effective amount of a conjugate comprising a targeting peptide and a cytokine, where the targeting peptide is a peptide containing an NGR motif, isoDGR or RGD, and where the cytokine is TNFα or TNFβ, together with pharmaceutically acceptable carriers and diluents, for use in the treatment of mesothelioma. ! 7. The pharmaceutical composition according to claim 6, where the conjugate contains TNF associated with the targeting peptide CNGRC through the spacer G.! 8. A pharmaceutical composition comprising a conjugate containing TNF coupled to the CNGRC targeting peptide via spacer G, in a concentration in the range of 0.01 to 10 mg / ml, together with pharmaceutically acceptable carriers and diluents for use in the treatment of mesothelium1. Конъюгат, содержащий нацеливающий пептид и цитокин, для применения при лечении мезотелиомы, где нацеливающий пептид представляет собой пептид, содержащий мотив NGR, изоDGR ил
